News

AstraZeneca to launch eculizumab in India this August for rare blood disordersAstraZeneca Pharma India is set to launch Eculizumab (Soliris) in August 2025, targeting the treatment of rare blood disorders PNH and aHUS. The drug inhibits complement-mediated thrombotic microangiopathy and received CDSCO approval earlier this year.By Megha Rani   August 6, 2025, 3:52:12 PM IST (Published)2 Min ReadAstraZeneca Pharma India Ltd has announced its plans to launch Eculizumab, marketed under the brand name Soliris, in India this August. The drug is intended for the treatment of rare and severe blood disorders.

Earlier this year in January, AstraZeneca received regulatory clearance from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute the drug across India. The approval was granted in Form CT-20 by the Drugs Controller General of India, officially allowing the sale of Eculizumab concentrate for infusion 300 mg (10mg/ml).

Soliris is indicated for use in patients suffering from Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)—both are life-threatening conditions that involve the destruction of blood cells and damage to blood vessels. By targeting complement-mediated thrombotic microangiopathy, the drug helps manage symptoms and prevent further complications.

Eculizumab is a special type of medicine called a monoclonal antibody. It helps treat two rare and serious health problems—PNH and aHUS.

PNH causes red blood cells to break down, which can lead to blood clots and damage to organs. aHUS affects the way blood clots in the body and can cause kidney failure and other dangerous issues.

This medicine works by blocking a harmful process in the body that causes small blood vessels to get clogged, which is part of what makes both conditions so risky.

Also Read: Electricity bills to rise as SC asks states, UTs to clear ₹1.5 lakh crore dues in four years

Shares of AstraZeneca Pharma India Ltd ended lower on Wednesday by 0.24% at ₹8,834.00 on NSE.Continue Reading(Edited by : Ajay Vaishnav)Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsAstraZenecadrugspharma stocks